HUTCHMED (NASDAQ:HCM) Sets New 1-Year Low – Time to Sell?

Posted by Francis Steltz on Jun 16th, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $10.40 and last traded at $10.5310, with a volume of 13101 shares. The stock had previously closed at $10.83.

Analyst Ratings Changes

HCM has been the subject of a number of analyst reports. Morgan Stanley set a $13.60 price objective on HUTCHMED in a research note on Thursday, May 28th. Bank of America reduced their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Finally, Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $16.80.

Get Our Latest Research Report on HUTCHMED

HUTCHMED Stock Performance

The company has a fifty day simple moving average of $13.02 and a two-hundred day simple moving average of $13.91. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

Institutional Trading of HUTCHMED

A number of institutional investors have recently modified their holdings of the company. State Street Corp lifted its holdings in shares of HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after purchasing an additional 3,801 shares in the last quarter. M&G PLC lifted its holdings in shares of HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares in the last quarter. Amundi lifted its holdings in shares of HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares in the last quarter. Finally, UBS Group AG lifted its holdings in shares of HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after purchasing an additional 72,614 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.